GlassScriptPhysician profile
Melissa Real
NPI 1326675414
$5,370.74
in general payments reported to CMS, 2019-2025
18 companies · $2,309 in 2025
The $2,309 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.73 · 2023: $630 · 2024: $2,409 · 2025: $2,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,347.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $1,279.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $895.32 | 2023-2025 | Vemlidy |
| Abbvie INC. | $867.64 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.42 | 2023-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $403.12 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $310.88 | 2023-2025 | Zepbound, Mounjaro |
| Intercept Pharmaceuticals, INC. | $189.13 | 2023-2024 | Ocaliva |
| Boston Scientific Corporation | $143.22 | 2024-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | |
| Fujifilm Healthcare Americas Corporation | $121.36 | 2024 | Utaswako Afp-L3 |
| Mallinckrodt Hospital Products INC. | $119.27 | 2023-2024 | Terlivaz |
| Mirum Pharmaceuticals, INC. | $113.55 | 2024-2025 | Livmarli |
| Genentech USA, INC. | $108.47 | 2023-2024 | Tecentriq |
| Tersera Therapeutics LLC | $50.38 | 2025 | Xermelo |
| Novo Nordisk INC | $36.72 | 2024-2025 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $34.60 | 2025 | Givlaari |
| Eisai INC. | $29.77 | 2025 | |
| Hologic Sales and Service, LLC | $23.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Real listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.